13 research outputs found
Π₯ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ ΠΏΡΠ΅Π΄ΠΏΠ»Π΅ΡΡΡ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ Π²ΡΠΎΠΆΠ΄Π΅Π½Π½ΡΠΌ ΡΠ°Π΄ΠΈΠΎΡΠ»ΡΠ½Π°ΡΠ½ΡΠΌ ΡΠΈΠ½ΠΎΡΡΠΎΠ·ΠΎΠΌ: ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
Background. Congenital radioulnar synostosis (CRUS) may have a negative impact on the function of the upper limb and cause disability. The main aim of the surgical treatment is to correct the forearm position for diminishing functional limitations.
The study aimed to analyze the variety of surgical methods for correction of the pronation forearm deformity in children with congenital radioulnar synostosis based on the literature data.
Methods. We have searched publications in eLIBRARY, PubMed (MEDLINE), Ovid, ScienceDirect, Google Scholar databases. The analysis has included the age at surgery, indications for surgery, the target functional forearm position, the time of consolidation of the forearm bones, the frequency of neurovascular complications.
Results. Most authors considered subjective complaints as the main indication for surgical treatment, while some researchers recommended taking into account the forearm hyperpronation position. The median age of the surgical treatment was 5.17 years (3.25-9.46). The medians of the recommended forearm positions for unilateral CRUS were 0-10 of pronation for the dominant, and 0-12.5 of supination for the non-dominant limb; with bilateral cases 0-17.5 pronation for the dominant and 0-12 supination for the non-dominant limb. Median of the osteotomy consolidation time varied from 6 to 8 weeks. The maximal time of forearm bone consolidation was significantly higher (p = 0.024) in the group with osteotomies through the synostosis site. Though the target forearm position was achieved in all cases, the number of complications in the proximal osteotomy group was statistically significantly different (p0.01). The chances of neurovascular complications were 20.5 times higher in the group of patients who underwent osteotomy through the synostosis (95% CI: 2.7-155.6).
Conclusions. The problem of surgical treatment of children with CRUS in the world medical practice remains relevant despite the wide range of proposed methods. The development of an algorithm regarding the need for surgical treatment and its methodology requires further high-quality research.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΡΠΎΠΆΠ΄Π΅Π½Π½ΡΠΉ ΡΠ°Π΄ΠΈΠΎΡΠ»ΡΠ½Π°ΡΠ½ΡΠΉ ΡΠΈΠ½ΠΎΡΡΠΎΠ· (ΠΠ Π£Π‘), Π±ΡΠ΄ΡΡΠΈ ΡΠ΅Π΄ΠΊΠΎΠΉ Π°Π½ΠΎΠΌΠ°Π»ΠΈΠ΅ΠΉ ΡΠ°Π·Π²ΠΈΡΠΈΡ, ΠΌΠΎΠΆΠ΅Ρ ΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΡΡΠ½ΠΊΡΠΈΡ Π²Π΅ΡΡ
Π½Π΅ΠΉ ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΡΡΠΈ, Π·Π°ΡΡΡΠ΄Π½ΡΡΡ ΡΠ°ΠΌΠΎΠΎΠ±ΡΠ»ΡΠΆΠΈΠ²Π°Π½ΠΈΠ΅. ΠΡΠ½ΠΎΠ²Π½Π°Ρ Π·Π°Π΄Π°ΡΠ° Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ ΠΏΡΠ΅Π΄ΠΏΠ»Π΅ΡΡΡ Ρ ΡΠ΅Π»ΡΡ ΡΠ°ΡΡΠΈΡΠ΅Π½ΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠ΅ΠΉ.
Π¦Π΅Π»Ρ Π°Π½Π°Π»ΠΈΠ· Π΄Π°Π½Π½ΡΡ
Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΎ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ΅ΡΠΎΠ΄Π°Ρ
ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ ΠΏΡΠΎΠ½Π°ΡΠΈΠΎΠ½Π½ΠΎΠΉ Π΄Π΅ΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΏΡΠ΅Π΄ΠΏΠ»Π΅ΡΡΡ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ Π²ΡΠΎΠΆΠ΄Π΅Π½Π½ΡΠΌ ΡΠ°Π΄ΠΈΠΎΡΠ»ΡΠ½Π°ΡΠ½ΡΠΌ ΡΠΈΠ½ΠΎΡΡΠΎΠ·ΠΎΠΌ.
ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠΎΠΈΡΠΊ ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΉ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ Π² Π±Π°Π·Π°Ρ
Π΄Π°Π½Π½ΡΡ
eLIBRARY, PubMed (MEDLINE), Ovid, ScienceDirect, Google Scholar. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΡΡΠΎΠΊΠΈ ΠΊΠΎΠ½ΡΠΎΠ»ΠΈΠ΄Π°ΡΠΈΠΈ ΠΊΠΎΡΡΠ΅ΠΉ ΠΏΡΠ΅Π΄ΠΏΠ»Π΅ΡΡΡ, Π²ΠΎΠ·ΡΠ°ΡΡ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ, ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΡ ΠΊ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ, ΡΠ΅Π»Π΅Π²ΠΎΠ΅ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ ΠΏΡΠ΅Π΄ΠΏΠ»Π΅ΡΡΡ, ΡΠ°ΡΡΠΎΡΠ° Π½Π΅ΠΉΡΠΎΠ²Π°ΡΠΊΡΠ»ΡΡΠ½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π²Π°ΡΠΈΠ°Π½ΡΠ° ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²ΠΎΠΌ Π°Π²ΡΠΎΡΠΎΠ² ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°Π½ΠΎ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Π° ΠΏΡΠΈ Π½Π°Π»ΠΈΡΠΈΠΈ ΡΡΠ±ΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΆΠ°Π»ΠΎΠ±, Π½Π΅ΠΊΠΎΡΠΎΡΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΠΈ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΡΡΡ ΡΡΠΈΡΡΠ²Π°ΡΡ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π³ΠΈΠΏΠ΅ΡΠΏΡΠΎΠ½Π°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ ΠΏΡΠ΅Π΄ΠΏΠ»Π΅ΡΡΡ. ΠΠ΅Π΄ΠΈΠ°Π½Π° Π²ΠΎΠ·ΡΠ°ΡΡΠ° Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 5,17 Π»Π΅Ρ (3,259,46). ΠΠ΅Π΄ΠΈΠ°Π½Ρ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΡΠ΅ΠΌΡΡ
ΡΠ΅Π»Π΅Π²ΡΡ
ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ ΠΏΡΠΈ ΠΎΠ΄Π½ΠΎΡΡΠΎΡΠΎΠ½Π½Π΅ΠΌ ΠΠ Π£Π‘ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ Π΄Π»Ρ Π΄ΠΎΠΌΠΈΠ½Π°Π½ΡΠ½ΠΎΠΉ ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΡΡΠΈ 010 ΠΏΡΠΎΠ½Π°ΡΠΈΠΈ, Π΄Π»Ρ ΡΡΠ±Π΄ΠΎΠΌΠΈΠ½Π°Π½ΡΠ½ΠΎΠΉ 012,5 ΡΡΠΏΠΈΠ½Π°ΡΠΈΠΈ; ΠΏΡΠΈ Π΄Π²ΡΡΡΠΎΡΠΎΠ½Π½Π΅ΠΌ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠΈ 017,5 ΠΏΡΠΎΠ½Π°ΡΠΈΠΈ Π΄Π»Ρ Π΄ΠΎΠΌΠΈΠ½Π°Π½ΡΠ½ΠΎΠΉ ΠΈ 012 ΡΡΠΏΠΈΠ½Π°ΡΠΈΠΈ Π΄Π»Ρ ΡΡΠ±Π΄ΠΎΠΌΠΈΠ½Π°Π½ΡΠ½ΠΎΠΉ ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΡΡΠ΅ΠΉ. ΠΠ΅Π΄ΠΈΠ°Π½Ρ ΡΡΠΎΠΊΠΎΠ² ΠΊΠΎΠ½ΡΠΎΠ»ΠΈΠ΄Π°ΡΠΈΠΈ Π·ΠΎΠ½ ΠΎΡΡΠ΅ΠΎΡΠΎΠΌΠΈΠΈ Π²Π°ΡΡΠΈΡΡΡΡ ΠΎΡ 6 Π΄ΠΎ 8 Π½Π΅Π΄. ΠΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΡΠ΅ ΡΡΠΎΠΊΠΈ ΠΊΠΎΠ½ΡΠΎΠ»ΠΈΠ΄Π°ΡΠΈΠΈ ΠΊΠΎΡΡΠ΅ΠΉ ΠΏΡΠ΅Π΄ΠΏΠ»Π΅ΡΡΡ Π² Π³ΡΡΠΏΠΏΠ΅ ΠΎΡΡΠ΅ΠΎΡΠΎΠΌΠΈΠΉ ΡΠ΅ΡΠ΅Π· Π·ΠΎΠ½Ρ ΡΠΈΠ½ΠΎΡΡΠΎΠ·Π° ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ (Ρ = 0,024) Π²ΡΡΠ΅ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ Π³ΡΡΠΏΠΏΠΎΠΉ ΠΎΡΡΠ΅ΠΎΡΠΎΠΌΠΈΠΉ ΠΎΠ±Π΅ΠΈΡ
ΠΊΠΎΡΡΠ΅ΠΉ ΠΏΡΠ΅Π΄ΠΏΠ»Π΅ΡΡΡ. ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° ΡΠΎ, ΡΡΠΎ ΡΠ΅Π»Π΅Π²ΠΎΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ ΠΏΡΠ΅Π΄ΠΏΠ»Π΅ΡΡΡ Π΄ΠΎΡΡΠΈΠ³Π½ΡΡΠΎ Π²ΠΎ Π²ΡΠ΅Ρ
ΡΠ»ΡΡΠ°ΡΡ
, ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π² Π³ΡΡΠΏΠΏΠ΅ ΠΏΡΠΎΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΡΡ
ΠΎΡΡΠ΅ΠΎΡΠΎΠΌΠΈΠΉ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ ΠΎΡΠ»ΠΈΡΠ°Π»ΠΎΡΡ (p0,01). Π¨Π°Π½ΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π½Π΅ΠΉΡΠΎΠ²Π°ΡΠΊΡΠ»ΡΡΠ½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π² 20,5 ΡΠ°Π· Π²ΡΡΠ΅ Π² Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΊΠΎΡΠΎΡΡΠΌ Π²ΡΠΏΠΎΠ»Π½ΡΠ»ΠΈ ΠΎΡΡΠ΅ΠΎΡΠΎΠΌΠΈΡ ΡΠ΅ΡΠ΅Π· Π·ΠΎΠ½Ρ ΡΠΈΠ½ΠΎΡΡΠΎΠ·Π° (95% ΠΠ: 2,7155,6).
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΎΠ±Π»Π΅ΠΌΠ° Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄Π΅ΡΠ΅ΠΉ Ρ ΠΠ Π£Π‘ Π² ΠΌΠΈΡΠΎΠ²ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅, Π½Π΅ΡΠΌΠΎΡΡΡ Π½Π° ΡΠΈΡΠΎΠΊΠΈΠΉ ΡΠΏΠ΅ΠΊΡΡ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ, ΠΎΡΡΠ°Π΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ. Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° Π°Π»Π³ΠΎΡΠΈΡΠΌΠ° ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ Π΅Π³ΠΎ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ ΡΡΠ΅Π±ΡΠ΅Ρ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π³ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π²ΡΡΠΎΠΊΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΡΠ²Π°
Π‘ΠΠΠΠ ΠΠΠΠΠ ΠΠΠΠΠΠΠ, ΠΠΠΠΠΠΠΠΠΠ Π ΠΠ ΠΠΠΠΠ ΠΠ Π Π ΠΠΠΠΠ’ΠΠ ΠΠΠ‘Π£ΠΠΠΠΠ ΠΠΠΠ‘Π’ΠΠΠ’ΠΠΠ‘Π’Π Π£ ΠΠΠ¦ΠΠΠΠ’ΠΠ Π‘ ΠΠΠ€ΠΠ ΠΠ’ΠΠ ΠΠΠΠΠΠ ΠΠ
Aim. The estimate insulin resistance in myocardial infarction. Patients and methods. The study involved 200 patients with myocardial infarction, in which on the 1st and 12th day of hospitalization measured glucose, insulin, insulin resistance index (IR), lipid profile, the concentration of adipokines and ghrelin. Results. IR was detected in 77% of patients and was associated with a history of factors of cardiovascular risk, adverse clinical course of the disease, lipid disorders. The most important marker was the level of free fatty acids. High risk associated with increased in 9 times the concentration of free fatty acids in blood plasma. Patients with IR observed increased concentrations of leptin, resistin, and reduced the protective effect of adiponectin. The high specificity and sensitivity characteristic of the concentration of ghrelin: its reduction by 4 times in the acute phase of myocardial infarction increases the risk of MI by 78%. Conclusions. Significant risk factors for MI myocardial infarction, along with insulinemia and glycemia, is to increase the concentration of free fatty acids and the disbalance in the system adipokines against deficiency of ghrelin in acute and early recovery periods of the disease. Free fatty acids and ghrelin are promising markers to stratify the risk of insulin resistance in patients with myocardial infarction.Β Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΎΡΠ΅Π½ΠΊΠ° ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈ ΠΈΠ½ΡΠ°ΡΠΊΡΠ΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°. ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: Β Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 200 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΈΠ½ΡΠ°ΡΠΊΡΠΎΠΌ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°,Β Β Ρ ΠΊΠΎΡΠΎΡΡΡ
Π½Π° 1-Π΅ ΠΈ 12-Π΅ ΡΡΡ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ Π³Π»ΡΠΊΠΎΠ·Ρ, ΠΈΠ½ΡΡΠ»ΠΈΠ½Π°, ΠΈΠ½Π΄Π΅ΠΊΡ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ (ΠΠ ), ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ, ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ Π°Π΄ΠΈΠΏΠΎΠΊΠΈΠ½ΠΎΠ² ΠΈ Π³ΡΠ΅Π»ΠΈΠ½Π°. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΠ Π±ΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π° Ρ 77% Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π»Π°ΡΡ Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅ ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠ³ΠΎ ΡΠΈΡΠΊΠ°, Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, Π½Π°ΡΡΡΠ΅Π½ΠΈΠ΅ΠΌ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π°. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΡΠΌ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ ΠΎΠΊΠ°Π·Π°Π»ΡΡ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΡ
ΠΆΠΈΡΠ½ΡΡ
ΠΊΠΈΡΠ»ΠΎΡ. ΠΡΡΠΎΠΊΠΈΠΉ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΠ ΡΠ²ΡΠ·Π°Π½ Ρ Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π½ΠΈΠ΅ΠΌΒ Π² 9 ΡΠ°Π· ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΡ
ΠΆΠΈΡΠ½ΡΡ
ΠΊΠΈΡΠ»ΠΎΡ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ. Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠ Π½Π°Π±Π»ΡΠ΄Π°Π΅ΡΡΡ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π»Π΅ΠΏΡΠΈΠ½Π°, ΡΠ΅Π·ΠΈΡΡΠΈΠ½Π°, ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π·Π°ΡΠΈΡΠ½ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π°Π΄ΠΈΠΏΠΎΠ½Π΅ΠΊΡΠΈΠ½Π°. ΠΡΡΠΎΠΊΠ°Ρ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ ΠΈ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½Π° Π΄Π»Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π³ΡΠ΅Π»ΠΈΠ½Π°: Π΅Π΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π² 4 ΡΠ°Π·Π° Π² ΠΎΡΡΡΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΈΠ½ΡΠ°ΡΠΊΡΠ° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΠ Π½Π° 78%.ΠΡΠ²ΠΎΠ΄Ρ: Π·Π½Π°ΡΠΈΠΌΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΈΡΠΊΠ° ΠΠ ΠΏΡΠΈ ΠΈΠ½ΡΠ°ΡΠΊΡΠ΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°, Π½Π°ΡΡΠ΄Ρ Ρ ΠΈΠ½ΡΡΠ»ΠΈΠ½Π΅ΠΌΠΈΠ΅ΠΉ ΠΈ Π³Π»ΠΈΠΊΠ΅ΠΌΠΈΠ΅ΠΉ, ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅Β ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Β ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΡ
ΠΆΠΈΡΠ½ΡΡ
ΠΊΠΈΡΠ»ΠΎΡ ΠΈ Π΄ΠΈΡΠ±Π°Π»Π°Π½Ρ Π² ΡΠΈΡΡΠ΅ΠΌΠ΅ Π°Π΄ΠΈΠΏΠΎΠΊΠΈΠ½ΠΎΠ²Β Β Π½Π° ΡΠΎΠ½Π΅ Π΄Π΅ΡΠΈΡΠΈΡΠ° Π³ΡΠ΅Π»ΠΈΠ½Π° Π² ΠΎΡΡΡΠΎΠΌ ΠΈ ΡΠ°Π½Π½Π΅ΠΌ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π°Ρ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π‘Π²ΠΎΠ±ΠΎΠ΄Π½ΡΠ΅ ΠΆΠΈΡΠ½ΡΠ΅ ΠΊΠΈΡΠ»ΠΎΡΡ ΠΈ Π³ΡΠ΅Π»ΠΈΠ½ ΡΠ²Π»ΡΡΡΡΡ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠ°ΠΌΠΈ Π΄Π»Ρ ΡΡΡΠ°ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΈΠ½ΡΠ°ΡΠΊΡΠΎΠΌΒ Β ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°.
Arctic coastal transit and cyclic aquatic systems' hydrological and geochemical particularities
Modulation of the primary astrocyte-enriched culturesβ oxylipin profiles reduces neurotoxicity
Recently, manipulations with reactive astrocytes have been viewed as a new therapeutic approach that will enable the development of treatments for acute brain injuries and neurodegenerative diseases. Astrocytes can release several substances, which may exert neurotoxic or neuroprotective effects, but the nature of these substances is still largely unknown. In the present work, we tested the hypothesis that these effects may be attributed to oxylipins, which are synthesized from n-3 or n-6 polyunsaturated fatty acids (PUFAs). We used astrocyte-enriched cultures and found that: (1) lipid fractions secreted by lipopolysaccharide (LPS)βstimulated rat primary astrocyte-enriched culturesβpossessed neurotoxic activity in rat primary neuronal cultures; (2) both of the tested oxylipin synthesis inhibitors, ML355 and Zileuton, reduce the LPS-stimulated release of interleukin 6 (IL-6) by astrocyte cultures, but only ML355 can change lipid fractions from neurotoxic to non-toxic; and (3) oxylipin profiles, measured by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) from neurotoxic and non-toxic lipid fractions, reveal a group of n-3 docosahexaenoic acid derivatives, hydroxydocosahexaenoic acids (HdoHEs)-4-HdoHE, 8-HdoHE, and 17-HdoHE, which may reflect the neuroprotective features of lipid fractions. Regulating the composition of astrocyte oxylipin profiles may be suggested as an approach for regulation of neurotoxicity in inflammatory processes. Β© 2021 by the authors. Licensee MDPI, Basel, Switzerland